; and (3) that contains such other information as the Secretary may require. (d) Amount of grant The amount of a grant under this section shall equal (to the extent practicable) the amount of funds received from State or local government sources for the research that is the subject of the grant. (e) Endemic orphan fungal disease defined The term endemic orphan fungal disease has the meaning given such term in section 529B of the Federal Food, Drug, and Cosmetic Act, as added by section 7. (f) Authorization of appropriations There are authorized to be appropriated to carry out this section $8,000,000 for each of fiscal years 2019 through 2024, to remain available until expended. (g) Sunset The Secretary may not award grants under this section on or after October 1, 2024. 5. FDA guidance for industry on development of diagnostics and antifungal drugs and vaccines for Valley Fever (a) In general Not later than one year after the date of the enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall issue draft guidance for industry for the purposes of assisting entities seeking approval under the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 301 et seq.) or licensure under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ) of antifungal therapies, diagnostics, or vaccines, specifically therapies, diagnostics, and vaccines designed to diagnose, treat, or prevent coccidioidomycosis (commonly known as Valley Fever). (b) Consultation In developing the draft guidance under subsection (a), the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall consult with institutions of higher education (as defined in section 101 of the Higher Education Act of 1965 ( 20 U.S.C. 1001 )), researchers, and other relevant stakeholders. (c) Final guidance The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall finalize the draft guidance issued under subsection (a) not later